Genscript Biotech Corporation (G51) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genscript Biotech Corporation (G51) has a cash flow conversion efficiency ratio of -0.045x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-93.58 Million ≈ $-109.41 Million USD) by net assets (€2.09 Billion ≈ $2.44 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See G51 equity to assets ratio to measure how much of total assets are equity-financed.
Genscript Biotech Corporation - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Genscript Biotech Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check G51 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Genscript Biotech Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genscript Biotech Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Impinj Inc
NASDAQ:PI
|
0.072x |
|
Assured Guaranty Ltd
NYSE:AGO
|
0.034x |
|
Breville Group Ltd
AU:BRG
|
-0.006x |
|
Signet Jewelers Ltd
NYSE:SIG
|
-0.076x |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
-0.021x |
|
China Railway Construction Heavy Industry Corp Ltd
SHG:688425
|
0.024x |
|
MERCARI INC. UNSP.ADR/1/2
F:6TP0
|
-0.048x |
|
INVENTURUS KNOWLEDGE SO L
NSE:IKS
|
0.042x |
Annual Cash Flow Conversion Efficiency for Genscript Biotech Corporation (2016–2025)
The table below shows the annual cash flow conversion efficiency of Genscript Biotech Corporation from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Genscript Biotech Corporation (G51) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €3.96 Billion ≈ $4.64 Billion |
€325.52 Million ≈ $380.57 Million |
0.082x | +369.25% |
| 2024-12-31 | €4.32 Billion ≈ $5.05 Billion |
€75.65 Million ≈ $88.44 Million |
0.017x | +112.47% |
| 2023-12-31 | €2.04 Billion ≈ $2.39 Billion |
€-286.91 Million ≈ $-335.43 Million |
-0.140x | -58.98% |
| 2022-12-31 | €1.36 Billion ≈ $1.59 Billion |
€-120.29 Million ≈ $-140.63 Million |
-0.088x | +29.47% |
| 2021-12-31 | €1.09 Billion ≈ $1.28 Billion |
€-136.79 Million ≈ $-159.92 Million |
-0.125x | +32.44% |
| 2020-12-31 | €815.59 Million ≈ $953.51 Million |
€-151.09 Million ≈ $-176.64 Million |
-0.185x | -130.25% |
| 2019-12-31 | €372.30 Million ≈ $435.26 Million |
€-29.95 Million ≈ $-35.02 Million |
-0.080x | -112.90% |
| 2018-12-31 | €493.30 Million ≈ $576.72 Million |
€307.66 Million ≈ $359.69 Million |
0.624x | +566.40% |
| 2017-12-31 | €228.32 Million ≈ $266.93 Million |
€21.37 Million ≈ $24.98 Million |
0.094x | -48.24% |
| 2016-12-31 | €184.02 Million ≈ $215.14 Million |
€33.27 Million ≈ $38.90 Million |
0.181x | -- |
About Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Scien… Read more